Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-AON: Efgartigimod Alfa for Acute Optic Neuritis
NCT06453694Phase 2Recruiting
- Sponsor
- Anastasia Vishnevetsky
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of efgartigimod alfa in optic neuritis (ON), sponsored by Anastasia Vishnevetsky. Started Aug 2025; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
optic neuritis (ON)
Beyond the preview
Go deeper on NCT06453694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06453694.